ASMB

Assembly Biosciences Inc

ASMB.US assemblybio.com + Research + Basket
CIK 0001426800
Employees 73
Phone 833 509 4583
Fiscal year end December
IPO Dec 17, 2010
Address Two Tower Place, South San Francisco, CA, United States, 94080
20.50
+0.20 (+0.96%)
USD · NASDAQ
52-week range
19.30
39.71
Trading at 6% of the 52-week range
Market Cap
413.32M
P/E Ratio
19.52
Forward P/E
400.00
Book Value
15.40
Div. Yield
N/A
% Institutions
69.69%
% Insiders
27.66%

1 Year

-31.9%

3 Year

+94.4%

10 Year

-88.0%
Description

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Actions

Add an action for ASMB.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Jason A. Okazaki J.D. CEO, President & Director 1976
Dr. William E. Delaney IV, Ph.D. Chief Scientific Officer 1972
Dr. Anuj Gaggar M.D., Ph.D. Chief Medical Officer 1978
Ms. Jeanette M. Bjorkquist Principal Financial Officer, Executive Director of Accounting & Treasury 1987
Mr. Shannon Ryan Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management NA
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR Chief Human Resources Officer NA
Dr. Nicole S. White Ph.D. Chief Manufacturing Officer 1980
Ms. Katie Kitrinos Senior VP of Preclinical Research & Development NA
Mr. Thomas E. Rollins Executive Officer 1956
Amy Figueroa C.F.A. Investor Relations Consultant NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 31, 2025 Jeanette M Bjorkquist N/A Sale 180.00 $9.85 $1.77K SEC
Mar 31, 2025 John G Mchutchison N/A Sale 757.00 $9.85 $7.46K SEC
Mar 31, 2025 Jason A Okazaki N/A Sale 355.00 $9.85 $3.50K SEC
Dec 30, 2024 Michael Houghton N/A Purchase 3.20K $15.61 $49.98K SEC
Nov 18, 2024 Nicole S White N/A Sale 40.00 $16.29 $651.60 SEC
Oct 08, 2024 Alexander Schornstein N/A Purchase 10.00K $14.58 $145.80K SEC
Oct 03, 2024 Jason A Okazaki N/A Sale 197.00 $14.81 $2.92K SEC
Oct 03, 2024 Nicole S White N/A Sale 157.00 $14.81 $2.33K SEC
Jul 05, 2024 Alexander Schornstein N/A Purchase 4.44K $12.52 $55.56K SEC
Jul 03, 2024 Alexander Schornstein N/A Purchase 4.56K $12.29 $56.07K SEC
May 23, 2024 Jason A Okazaki N/A Sale 549.00 $14.93 $8.20K SEC
May 23, 2024 Jeanette M Bjorkquist N/A Sale 24.00 $14.93 $358.32 SEC
May 23, 2024 John G Mchutchison N/A Sale 2.12K $14.93 $31.61K SEC
Apr 30, 2024 Jason A Okazaki N/A Sale 1.57K $12.71 $19.94K SEC
Apr 30, 2024 Nicole S White N/A Sale 1.26K $12.71 $15.95K SEC
Apr 01, 2024 Jason A Okazaki N/A Sale 354.00 $13.07 $4.63K SEC
Apr 01, 2024 Jeanette M Bjorkquist N/A Sale 114.00 $13.07 $1.49K SEC
Apr 01, 2024 John G Mchutchison N/A Sale 1.21K $13.07 $15.76K SEC
Mar 27, 2024 Jason A Okazaki N/A Sale 392.00 $12.87 $5.05K SEC
Jan 17, 2024 Alexander Schornstein N/A Purchase 25.00K $9.36 $233.99K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Farallon Capital Management, L.L.C. 1.60M Jun 30, 2026 7.88% $0.20 30.71%
Paradigm Biocapital Advisors LP 1.55M Jun 30, 2026 7.63% $0.80 133.56%
COMMODORE CAPITAL LP 1.42M Jun 30, 2026 6.95% $2.32 41.50%
RA Capital Management, LLC 1.02M Jun 30, 2026 5.01% $0.24 0.00%
HHG PLC 849.31K Mar 31, 2026 4.17% $0.01 1.36%
Jupiter Topco LLC 849.31K Jun 30, 2026 4.17% $0.01 0.00%
BlackRock Inc 766.82K Jun 30, 2026 3.77% $0.00 278.22%
Parkman Healthcare Partners LLC 721.18K Jun 30, 2026 3.54% $2.03 75.37%
Vanguard Capital Management, LLC 558.94K Jun 30, 2026 2.75% $0.00 13.97%
Point72 Asset Management, L.P. 460.59K Jun 30, 2026 2.26% $0.01 33.85%
Seven Fleet Capital Management LP 433.15K Jun 30, 2026 2.13% $1.96 671.45%
Millennium Management LLC 298.81K Jun 30, 2026 1.47% $0.00 27.89%
Geode Capital Management, LLC 280.42K Jun 30, 2026 1.38% $0.00 110.89%
Schonfeld Strategic Advisors LLC 242.15K Jun 30, 2026 1.19% $0.02 100.96%
Ameriprise Financial Inc 230.00K Jun 30, 2026 1.13% $0.00 0.00%
DV EQUITIES, LLC 226.42K Jun 30, 2026 1.11% $0.89 0.00%
Aberdeen Group PLC 207.05K Jun 30, 2026 1.02% $0.01 0.00%
Affinity Asset Advisors, LLC 190.00K Jun 30, 2026 0.93% $0.24 0.00%
B Group, Inc 175.71K Jun 30, 2026 0.86% $2.27 0.00%
State Street Corp 171.93K Jun 30, 2026 0.84% $0.00 203.29%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 428.33K 2.10% ▲ 3.64% Sep 30, 2026
2 iShares Russell 2000 ETF 340.73K 1.67% ▼ 1.13% Sep 30, 2026
3 State Street® SPDR® S&P® Biotech ETF 303.71K 1.49% ▼ 1.87% Sep 30, 2026
4 iShares Russell 2000 Value ETF 123.43K 0.61% ▲ 0.15% Sep 30, 2026
5 Fidelity Small Cap Index 107.39K 0.53% ▲ 0.64% Jul 31, 2026
6 Vanguard Russell 2000 ETF 77.84K 0.38% ▲ 37.66% Sep 30, 2026
7 BlackRock Advantage Small Cap Core Instl 72.73K 0.36% ▲ 284.86% Sep 30, 2026
8 Franklin Biotechnology Discv A(acc)USD 72.22K 0.35% ▲ 0.00% Sep 30, 2026
9 Fidelity Extended Market Index 56.67K 0.28% ▲ 1.41% Aug 31, 2026
10 iShares Micro-Cap ETF 42.11K 0.21% ▼ 0.68% Sep 30, 2026

Financial Highlights

▼
Market Cap: $413.32M
EBITDA: $-8.69M
P/E Ratio: $19.52
PEG Ratio: $0.00
Book Value: $15.40
Earnings/Share: $1.04
Profit Margin: -0.06%
Operating Margin: -47.44%
ROA (TTM): -2.67%
ROE (TTM): -0.03%
Revenue (TTM): $74.85M
Revenue/Share (TTM): $4.57
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 38.90%

Valuation Metrics

Enterprise Value: $94.90M
Trailing P/E: 19.52
Forward P/E: 400.00

Shares Statistics

Shares Outstanding: 20.36M
Shares Float: 9.17M
% Insiders: 27.66%
% Institutions: 69.69%
Short % Float: 19.05%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$72.30M
Cost of Goods Sold
adjust
$-129.00K
Gross Profit
subtotal
$72.17M
SG&A
adjust
$-19.61M
R&D
adjust
$-64.81M
Operating Income
subtotal
$-12.12M
Other / Non-Operating Items
adjust
$6.00M
Net Income
subtotal
$-6.12M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ASMB.US!